HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy.

Abstract
Although malignant astrocytomas are a leading cause of cancer-related death in children, rational therapeutic strategies are lacking. We previously identified activating mutations of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) (BRAF(T1799A) encoding BRAF(V600E)) in association with homozygous cyclin-dependent kinase inhibitor 2A (CDKN2A, encoding p14ARF and p16Ink4a) deletions in pediatric infiltrative astrocytomas. Here we report that BRAF(V600E) expression in neural progenitors (NPs) is insufficient for tumorigenesis and increases NP cellular differentiation as well as apoptosis. In contrast, astrocytomas are readily generated from NPs with additional Ink4a-Arf deletion. The BRAF(V600E) inhibitor PLX4720 significantly increased survival of mice after intracranial transplant of genetically relevant murine or human astrocytoma cells. Moreover, combination therapy using PLX4720 plus the Cyclin-dependent kinase (CDK) 4/6-specific inhibitor PD0332991 further extended survival relative to either monotherapy. Our findings indicate a rational therapeutic strategy for treating a subset of pediatric astrocytomas with BRAF(V600E) mutation and CDKN2A deficiency.
AuthorsEmmanuelle Huillard, Rintaro Hashizume, Joanna J Phillips, Amélie Griveau, Rebecca A Ihrie, Yasuyuki Aoki, Theodore Nicolaides, Arie Perry, Todd Waldman, Martin McMahon, William A Weiss, Claudia Petritsch, C David James, David H Rowitch
JournalProceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 109 Issue 22 Pg. 8710-5 (May 29 2012) ISSN: 1091-6490 [Electronic] United States
PMID22586120 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Cyclin-Dependent Kinase Inhibitor p16
  • Indoles
  • PLX 4720
  • Piperazines
  • Pyridines
  • Sulfonamides
  • Braf protein, mouse
  • Proto-Oncogene Proteins B-raf
  • Extracellular Signal-Regulated MAP Kinases
  • palbociclib
Topics
  • Animals
  • Apoptosis (drug effects)
  • Astrocytoma (drug therapy, genetics, pathology)
  • Blotting, Western
  • Cell Differentiation (drug effects)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cells, Cultured
  • Child
  • Cyclin-Dependent Kinase Inhibitor p16 (antagonists & inhibitors, genetics, metabolism)
  • Extracellular Signal-Regulated MAP Kinases (metabolism)
  • Female
  • Humans
  • Immunohistochemistry
  • Indoles (pharmacology)
  • Mice
  • Mice, Inbred BALB C
  • Mice, Knockout
  • Mice, Nude
  • Mice, SCID
  • Neural Stem Cells (cytology, drug effects, metabolism)
  • Phosphorylation (drug effects)
  • Piperazines (pharmacology)
  • Proto-Oncogene Proteins B-raf (antagonists & inhibitors, genetics, metabolism)
  • Pyridines (pharmacology)
  • Sulfonamides (pharmacology)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: